

Attorney Docket No.  
Customer No. 03000  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING OPERATION

Applicant : Nobuto Yamamoto

Serial No. : Continuation Application of ASN 08/618,485,  
filed March 19, 1996

Filed : April 5, 2001

For : PREPARATION OF POTENT MACROPHAGE  
ACTIVATING FACTORS DERIVED FROM  
CLONED VITAMIN D BINDING PROTEIN  
AND ITS DOMAIN AND THEIR THERAPEUTIC  
USAGE FOR CANCER, HIV-INFECTION  
AND OSTEOPETROSIS

Group :

Examiner :

PRELIMINARY AMENDMENT

Commissioner of Patents  
Washington, DC 20231

Sir:

This application is being filed under 35 C.F.R. 1.53(b). THIS IS NOT A CPA  
NOR AN RCE, WE REQUEST THAT A NEW APPLICATION SERIAL NUMBER, PLEASE  
DO NOT ABANDON THE PARENT APPLICATION.

### IN THE SPECIFICATION

Please delete lines 25-27 on page 1.

Please amend the specification by inserting the following on page 1 in place thereof:

--This application is a Continuation Application of ASN 08/618,485, filed on March 19, 1996 entitled PREPARATION OF POTENT MACROPHAGE ACTIVATING FACTORS DERIVED FROM CLONED VITAMIN D BINDING PROTEIN AND ITS DOMAIN AND THEIR THERAPEUTIC USAGE FOR CANCER, HIV-INFECTION AND OSTEOPETROSIS which is a continuation-in-part of ASN 08/478,121 filed June 7, 1995, entitled DIAGNOSTIC PROGNOSTIC INDICES FOR CANCER AND AIDS, and the entire disclosures of which are incorporated by reference herein--.

### IN THE CLAIMS

Prior to calculating the filing fee, please cancel claims 1-4.

Please add the following claims.

--1. A process for cloning vitamin D<sub>3</sub>-binding protein (Gc protein) into baculovirus comprising the step of selecting and using a baculovirus non-fusion vector and a host to clone the vitamin D<sub>3</sub>-binding protein Gc protein (Gc protein), wherein the Gc protein has a molecular weight of approximately 52,000, approximately 458 amino acids and 3 distinct domains,

by using cDNA containing initiation codon (-16 Met) through the leader sequence to the +1 amino acid (leu of native Gc protein and introducing the cDNA

to the non-fusion vector with a polylinker carrying the EcoRI site,  
isolating a full-length Gc cDNA with EcoRI termini,  
digesting the cDNA for Gc protein with EcoRI enzyme, and  
ligating with a ligase to produce a construct to express the Gcprotein.

2. A process for producing a cloned macrophage activating factor (GcMAFc) comprising contacting cloned Gc protein a molecular weight of approximately 52,000, approximately 458 amino acids and 3 distinct domains in vitro with immobilized beta-galactosidase and sialidase and obtaining the cloned macrophage activating factor (GcMAFc).

3. A process for producing a cloned macrophage activating factor (GcMAFc) made in accordance with the process of claim 1 comprising contacting cloned Gc protein in vitro with immobilized beta-galactosidase and sialidase and obtaining the cloned macrophage activating factor (GcMAFc).--

The Commissioner of Patents is hereby authorized to charge any fees which may be required, and to credit any overpayment to Account No. 03-0075. A duplicate copy of this sheet is enclosed.


Enclosed is a copy of the prior application, including the Declaration as originally filed.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,  
COHEN & POKOTILOW, LTD.

April 5, 2001

By



Robert S. Silyer  
12<sup>th</sup> Floor, Seven Penn Center  
1635 Market Street  
Philadelphia, PA 19103-2212  
(215) 567-2010  
Attorney for Applicant